|
Uppsala, Sweden, February 13, 2007
Gyros introduces new product for high concentration
protein quantification
Gyros announced today that it has extended its product range
with a new compact disc (CD) microlaboratory – Gyrolab
Bioaffy® 20 HC – for dilution-free protein quantification
in the grams per liter range. |
|
When quantifying proteins in high concentrations, current
technologies, such as ELISA, require extensive dilution of samples
in order to bring them into the technology’s measurable range. This
is cumbersome and time consuming for scientists and increases the
risk of quantification errors. By using very small sample volumes
and a high-capacity capture column, Gyrolab Bioaffy 20 HC increases
the measurement range, allowing scientists to quantify proteins in
the grams per liter range without the need for any pre-assay, sample
dilution.
Both the new Gyrolab Bioaffy 20 HC and the existing Gyrolab
Bioaffy 200 (for high sensitivity assays when detecting low
concentrations) CD microlaboratories are run on the same fully
automated instrument, Gyrolab® Workstation. As such, scientists are
able to run a diverse range of applications all using a single
instrument. The open design principle underlying the platform
provides very wide flexibility in the choice of target protein and
allows experimental set-up to be designed on a day-to-day basis.
|
|
An example application where the introduction of
Gyrolab Bioaffy 20 HC can greatly support the work of scientists is
in process development for the production of protein-based drugs
(biopharmaceuticals), such as monoclonal IgG. The combination of
Gyrolab Bioaffy 20 HC and Gyrolab Bioaffy 200 can be used to
increase the efficiency of biopharmaceutical process development by
quickly and accurately quantifying drug product and host cell
proteins at concentrations relevant for the entire purification
process, from cell supernatant to purified product.
Commenting on the launch, Jan Würtz, Gyros CEO, said, “The new CD
microlaboratory is an important addition to our product line and
extends the value of our offering to our growing customer base. It
also shows the versatility of our technology to meet different
application needs. Obviously, it strengthens our position for new
sales activity as well, and means that we can now offer a complete,
single system solution with an extremely broad measurement range –
something that is particularly well suited to biotherapeutic
applications.” |
|
About Gyros AB
Gyros is the leader in the
miniaturization and integration of laboratory applications through
its proprietary microfluidics platform, Gyrolab CD (compact disc)
microlaboratory. Gyros delivers simple to use, precisely controlled
solutions for processing hundreds of samples in parallel, generating
more information from less sample and improving lab productivity and
efficiency.
Application-specific microlaboratories use a modular design
offering the potential to run different applications on a single
instrument and to create customized solutions. The company is
currently focused on two market segments: quantitative protein
analysis for research, drug discovery and development applications;
and, in vitro diagnostics for medical applications. Gyros has 50
employees working at its headquarters and European sales office in
Uppsala, Sweden and its sales office in the USA.
For further information, visit www.gyros.com or contact:
Jan
Würtz, President and CEO, Gyros AB
Tel: +46 (0)18 566 400
Mobile: +46 (0)70 592 5670
jan.wurtz@gyros.com
Christina Burtsoff Asp, VP Marketing, Gyros AB
Tel: +46 (0)18
566 404
Mobile: +46 (0)70 666 1642
christina.asp@gyros.com
------------------------------------------------------------------------------------------------
Statements
in this press release that are not strictly historical may be
forward-looking and include risks and uncertainties. Therefore,
though based on Gyros’ current expectations, it should be duly noted
that a variety of factors could cause actual results and experiences
to differ materially from what is herein expressed. Risks and
uncertainties include, but are not limited to, risks associated with
the management of growth and international operations (including
effects of currency fluctuations), variability of operating results,
unforeseen changes in the diagnostic and pharmaceutical markets,
market competition, rapid or unexpected changes in technologies,
fluctuations in product demand, difficulties to successfully
develop, adapt, produce or commercialize products, the ability to
identify and develop new products and to differentiate products from
those of competitors, as well as various legal
hazards.
------------------------------------------------------------------------------------------------
|
